HRD in clinical practice: where are we now?
Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. Currently, numerous methods of HRD detection exist but understanding the different ways to measure HRD and discuss their respective validation level is important for their appropriate use in clinical practice.
Watch the recording now
Monday 22nd May 2023 / 2:30pm - 4:00pm CET.
During this webinar, we had the opportunity to have the clinician’s visions and an overview on the different HRD solutions available (academic and commercial) realized by two experts in molecular biologist.
This event was moderated by the Prof. Pascal Pujol who is the President of the SFMPP and who is working with an European expert group on a proposal European HRD testing joint consensus.
Agenda:
- Diaceutics - Welcome & introduction to Diaceutics.
- Prof. Pascal Pujol - HRD general introduction: where are we now?
- Prof. Isabelle Ray-Coquard - HRD in clinical practice.
- All participants (moderated by Prof. Pascal Pujol) - Discussion and questions.
- Prof. Alexandre Harlé and Prof. Diether Lambrechts - New methods available in Europe.
- All participants (moderated by Prof. Pascal Pujol) - Discussion and questions.
- Prof. Pascal Pujol - Conclusion
Speaker name: Prof. Pascal Pujol
University Hospital of Montpellier, Montpellier, France
Prof. Pascal Pujol is Professor of Medicine at the Montpellier Faculty of Medicine and President of the French Society of Predictive and Personalized Medicine. He heads the department of Cancer and Genetics at the University Hospital of Montpellier.
He is co-author of more than 200 publications. He conducts research work atCNRS and has coordinated severalphase III/IV clinical trials.
Speaker name: Prof. Isabelle RAY-COQUARD
CENTRE LEON BERARD
Prof. Ray-Coquard obtained her medical degree in 1997 specializing in oncology. In 2003 she received her PhD from the Université Claude Bernard for her research on the independents factors that determine medical practices in oncology. She also received Master’s degrees in in statistics in 1995 and in medical economy in 1996. From 2008 to 2013, she has served as Chairman of the gynaecologic group for clinical trials of the French National Cancer Institute (INCA) and she is currently the Network Director of the national network dedicated to diagnosis and management of the rare gynecological cancer (www.ovaire-rare.org), a network funded by the INCA commission.
Speaker name: Prof. Alexandre Harlé
Biopathology Department, ICL/CHRU Nancy
Prof. Alexandre Harlé obtained a PhD in Pharmacy and a PhD in molecular biology from the Nancy University. Prof. Alexandre Harléis PU-PH and work as Pharmacist-biologist on the INCaplatform in the Biopathology department ICL/CHRU of Nancy. Alexandre is specialized in the solid tumours analysis and started working on theHomologous recombination repair deficienciesin different cancer types, as well on paraffin-embedded tissues than in liquid biopsy.
Speaker name: Prof. Diether Lambrechts
VIB Center for Cancer Biology and University of Leuven, Belgium
Prof. Diether Lambrechts is Group Leader at the VIB and Professor at the University of Leuven, Belgium. Prof. Lambrechts was trained as an engineer at the University of Leuven where he also pursued his PhD. He then worked at the Wellcome Trust Centre for Human Genetics at the University of Oxford, UK, before joining the VIB as an independent Group Leader in 2008. He has won several awards: the Karel-Lodewijk Award for Human Medicine; the Galenus Prize for Pharmacology; the AstraZeneca Award for Translational Research and the Agilent Thought Leadership Award.